Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2024-07-09 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations regarding the disclosure of the total number of voting rights and shares outstanding as of a specific date (June 30, 2024). This type of periodic disclosure, which reports on the capital structure and voting rights, is a specific regulatory requirement. While it relates to share capital, it is not a general share issue announcement (SHA) or a transaction in own shares (POS). It is a mandatory disclosure of the current voting structure. Among the provided codes, none perfectly match a 'Monthly Voting Rights Disclosure,' but it is a specific regulatory announcement concerning share capital structure and voting rights. This fits best under the general 'Regulatory Filings' (RNS) category as a specific, non-financial report announcement, or potentially under 'Declaration of Voting Results & Voting Rights Announcements' (DVA) if interpreted broadly, although DVA usually refers to the *results* of a vote rather than the *basis* for voting (the total rights). Given the context of mandatory disclosure of capital structure figures, RNS is the most appropriate fallback for a specific regulatory filing that doesn't fit the core definitions of 10-K, ER, or IR. However, since the content is purely about the total number of voting rights, DVA is a strong candidate as it covers voting rights announcements. Since DVA is defined as 'Official results from shareholder votes at any general meeting,' and this is a monthly update on the *basis* for voting rights, RNS is safer as a general regulatory filing. Re-evaluating the options: This is a mandatory disclosure of the total number of shares and voting rights, often required monthly in France. This is a specific regulatory filing. It is not a proxy statement (PSI), dividend notice (DIV), or director dealing (DIRS). Given the options, RNS (Regulatory Filings) is the best fit for a mandatory, periodic, non-financial regulatory update.
2024-07-09 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (L.233-8 II du Code de commerce and 223-16 du Règlement Général de l'Autorité des Marchés Financiers) and provides a table detailing the total number of shares and voting rights as of June 30, 2024. This type of mandatory periodic disclosure regarding share capital structure and voting rights is a specific regulatory filing. While it is a periodic report, it is not a comprehensive financial report (10-K or IR). It is a specific disclosure about share capital changes/status. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit for mandatory disclosures concerning the total number of shares and voting rights, although 'RNS' (Regulatory Filings) is a strong fallback. Given the specific nature of reporting total voting rights and capital structure, SHA is more precise than the general RNS, as it directly relates to capital changes/status.
2024-07-09 French
Franchissements de seuils
Major Shareholding Notification Classification · 99% confidence The document is a formal declaration in French, dated July 2, 2024, concerning 'Déclarations de franchissements de seuils (article L. 233-7 du code de commerce)'. This explicitly refers to crossing ownership thresholds (5% capital/voting rights) in the company NANOBIOTIX by The Goldman Sachs Group, Inc. This type of filing, detailing changes in significant share ownership by an entity, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document details specific share counts, percentage changes, and references to French commercial code articles related to ownership disclosure, confirming it is not a general earnings release (ER), annual report (10-K), or a simple director's dealing (DIRS), but a notification of a major shareholder's position change.
2024-07-03 French
NANOBIOTIX ORGANISE UNE DISCUSSION VIRTUELLE ENTRE EXPERTS SUR LE POTENTIEL DE NBTXR3 EN IMMUNOTHÉRAPIE DANS LE CANCER DE LA TÊTE ET DU COU ET D’AUTRES INDICATIONS LE 18 JUIN 2024
Regulatory Filings Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a future event: a virtual expert discussion scheduled for June 18, 2024. It details the topic (NBTXR3 in immunotherapy for head and neck cancer), the participants (KOLs), and provides registration/webcast information. This is a corporate communication intended for immediate public dissemination regarding company activities, specifically an investor/medical event, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed interim report (IR). Since it is an announcement about an upcoming event/discussion, it fits best under the general category of corporate announcements. Given the options, it is a general corporate announcement that doesn't fit the highly specific categories like DIV, DIRS, or MANG. It is not a report itself, nor is it explicitly an announcement of a report publication (RPA). Therefore, the most appropriate fallback category is Regulatory Filings (RNS) for general corporate news releases that don't fit elsewhere, although it is functionally similar to an Investor Presentation announcement if the content were the presentation itself. However, as a press release announcing a future event/call, RNS is the best fit among the provided codes for non-standard, timely corporate news.
2024-06-12 French
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a future event: a virtual KOL event scheduled for June 18, 2024. It details the topic (NBTXR3 combined with immunotherapy) and provides registration links. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing results (like ER or AR). It is an announcement intended to inform investors and the public about upcoming corporate/scientific communication. Since it is a press release announcing an event/update, and it doesn't fit the specific categories like DIV, DIRS, or MANG, the most appropriate general category for a corporate announcement that isn't a formal report publication announcement (RPA) or a general regulatory filing (RNS) is often the closest fit based on content. However, given the options, this is a general corporate communication. It is not an Earnings Release (ER) as it's not announcing financial results, but a scientific/KOL event. It is not a Report Publication Announcement (RPA) because it is announcing an event, not the publication of a previously mentioned report. Given the nature of the announcement (a corporate update/event invitation), and lacking a specific 'Corporate Event Announcement' code, the best fit among the provided codes is often the general 'Regulatory Filings' (RNS) if it were a mandatory filing, or if it's purely promotional/informational, it might be considered a general Investor Relations communication. Since it is a press release announcing a future event and discussion of clinical data, it functions as a general corporate update. In the absence of a specific 'Press Release' or 'Investor Event Announcement' code, and noting that it is a formal communication disseminated to the public, RNS (Regulatory Filings/General Announcement) is the standard fallback for non-standard, yet important, corporate disclosures. However, if we strictly interpret the definitions, this is a communication about an upcoming event, which is often categorized as a general corporate disclosure. Given the options, RNS is the safest fallback for a press release that doesn't fit the specific financial/reporting codes.
2024-06-12 English
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release dated June 11, 2024, titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY." It explicitly references French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations regarding the disclosure of the total number of shares outstanding and voting rights, which is published monthly if there is a change. The core content is a table showing the share count and voting rights as of May 31, 2024. This type of mandatory periodic disclosure regarding the capital structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure concerning share capital. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the number of shares and voting rights, although it is a routine update rather than a major issuance announcement. However, given the nature of mandatory, periodic disclosure of share capital figures, and the lack of a specific 'Share Capital Update' code, 'SHA' is the most appropriate classification for this type of filing, which reports on the current state of the share base.
2024-06-11 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.